Relationship between Mixed Donor–Recipient Chimerism and Disease Recurrence after Hematopoietic Cell Transplantation for Sickle Cell Disease

Biology of Blood and Marrow Transplantation

Volumn 23, Issue 12, 2017, Pages 2178-2183

  Abraham, Allistair ^a   Hsieh, Matthew ^b,c   Eapen, Mary ^d   Fitzhugh, Courtney ^b,c   Carreras, Jeanette ^d   Keesler, Daniel ^d   Guilcher, Gregory ^e   Kamani, Naynesh ^f   Walters, Mark C ^g   Boelens, Jaap J ^h   Tisdale, John ^b,c   Shenoy, Shalini ⁱ  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e UNIVERSITY OF CALGARY   (Canada)

^f American Association of Blood Banks   (United States)

^g CHILDREN S HOSPITAL OAKLAND   (United States)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁱ WASHINGTON UNIVERSITY   (United States)

Author keywords

Disease symptoms; Mixed chimerism; Sickle cell disease; Transplant

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; HEMOGLOBIN S; MELPHALAN;

ACUTE CHEST SYNDROME; ADOLESCENT; ADULT; ARTICLE; BLOOD VESSEL OCCLUSION; CELL TRANSPLANTATION; CEREBROVASCULAR ACCIDENT; CHILD; CHIMERA; CONTROLLED STUDY; DONOR; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT REJECTION; HEMATOPOIETIC CELL; HUMAN; MAJOR CLINICAL STUDY; MYELOABLATIVE CONDITIONING; RECURRENT DISEASE; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; SICKLE CELL ANEMIA; AGED; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; MALE; MIDDLE AGED; PATHOLOGY; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANEMIA, SICKLE CELL; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBIN, SICKLE; HUMANS; MALE; MIDDLE AGED; RECURRENCE; TISSUE DONORS; TRANSPLANTATION CHIMERA; YOUNG ADULT;

EID: 85031102573     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2017.08.038     Document Type: Article

References (16)

1. Hartz, B., Marsh, R., Rao, K., et al. The minimum required level of donor chimerism in hereditary hemophagocytic lymphohistiocytosis. Blood 127 (2016), 3281–3290.
2. Marsh, R.A., Vaughn, G., Kim, M.O., et al. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood 116 (2010), 5824–5831.
3. Krishnamurti, L., Kharbanda, S., Biernacki, M.A., et al. Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant 14 (2008), 1270–1278.
4. Hsieh, M.M., Fitzhugh, C.D., Weitzel, R.P., et al. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. JAMA 312 (2014), 48–56.
5. Walters, M.C., Patience, M., Leisenring, W., et al. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant 7 (2001), 665–673.
6. Pai, S.Y., Logan, B.R., Griffith, L.M., et al. Transplantation outcomes for severe combined immunodeficiency, 2000-2009. N Engl J Med 371 (2014), 434–446.
7. Bernaudin, F., Socie, G., Kuentz, M., et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood 110 (2007), 2749–2756.
8. Hsieh, M.M., Kang, E.M., Fitzhugh, C.D., et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med 361 (2009), 2309–2317.
9. King, A.A., Kamani, N., Bunin, N., et al. Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies. Am J Hematol 90 (2015), 1093–1098.
10. Andreani, M., Testi, M., Gaziev, J., et al. Quantitatively different red cell/nucleated cell chimerism in patients with long-term, persistent hematopoietic mixed chimerism after bone marrow transplantation for thalassemia major or sickle cell disease. Haematologica 96 (2011), 128–133.
11. Locatelli, F., Rocha, V., Reed, W., et al. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood 101 (2003), 2137–2143.
12. Majumdar, S., Robertson, Z., Robinson, A., Starnes, S., Iyer, R., Megason, G., Outcome of hematopoietic cell transplantation in children with sickle cell disease, a single center's experience. Bone Marrow Transplant 45 (2010), 895–900.
13. Bacigalupo, A., Ballen, K., Rizzo, D., et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 15 (2009), 1628–1633.
14. Wu, C.J., Hochberg, E.P., Rogers, S.A., et al. Molecular assessment of erythroid lineage chimerism following nonmyeloablative allogeneic stem cell transplantation. Exp Hematol 31 (2003), 924–933.
15. Fitzhugh, C.D., Hsieh, M.M., Cordes, S., et al. At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic hematopoietic stem cell transplantation. Blood, 128, 2016, 2483.
16. Iannone, R., Casella, J.F., Fuchs, E.J., et al. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biol Blood Marrow Transplant 9 (2003), 519–528.